Q3 EPS Estimates for Globus Medical Boosted by Analyst

Globus Medical, Inc. (NYSE:GMED) – Zacks Research lifted their Q3 2025 earnings per share estimates for shares of Globus Medical in a report issued on Thursday, December 12th. Zacks Research analyst R. Department now anticipates that the medical device company will post earnings per share of $0.84 for the quarter, up from their previous forecast of $0.83. The consensus estimate for Globus Medical’s current full-year earnings is $2.97 per share. Zacks Research also issued estimates for Globus Medical’s Q2 2026 earnings at $0.98 EPS.

Several other research firms have also commented on GMED. Needham & Company LLC reissued a “hold” rating on shares of Globus Medical in a research report on Wednesday, November 6th. Canaccord Genuity Group boosted their target price on shares of Globus Medical from $85.00 to $92.00 and gave the stock a “buy” rating in a report on Monday, December 9th. Wells Fargo & Company raised their price target on shares of Globus Medical from $88.00 to $95.00 and gave the company an “overweight” rating in a report on Wednesday, December 11th. BTIG Research boosted their price objective on shares of Globus Medical from $87.00 to $91.00 and gave the stock a “buy” rating in a research note on Thursday, December 12th. Finally, Piper Sandler increased their target price on shares of Globus Medical from $80.00 to $100.00 and gave the company an “overweight” rating in a research report on Wednesday, November 6th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $93.55.

Globus Medical Stock Up 2.1 %

Shares of NYSE:GMED opened at $83.42 on Monday. The firm has a 50 day moving average of $79.31 and a 200 day moving average of $73.10. The company has a market capitalization of $11.36 billion, a price-to-earnings ratio of 124.51, a price-to-earnings-growth ratio of 1.99 and a beta of 1.19. Globus Medical has a 52 week low of $49.14 and a 52 week high of $87.22.

Globus Medical (NYSE:GMED) last announced its quarterly earnings results on Tuesday, November 5th. The medical device company reported $0.83 EPS for the quarter, beating the consensus estimate of $0.65 by $0.18. The firm had revenue of $625.71 million for the quarter, compared to analyst estimates of $604.69 million. Globus Medical had a return on equity of 9.98% and a net margin of 3.69%. The business’s revenue for the quarter was up 63.1% on a year-over-year basis. During the same quarter last year, the firm posted $0.57 earnings per share.

Insiders Place Their Bets

In other Globus Medical news, SVP Kelly Huller sold 2,500 shares of Globus Medical stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $87.00, for a total value of $217,500.00. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Daniel T. Scavilla sold 60,000 shares of the company’s stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $80.02, for a total value of $4,801,200.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 97,500 shares of company stock valued at $7,674,950. Corporate insiders own 18.54% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of GMED. V Square Quantitative Management LLC acquired a new stake in shares of Globus Medical in the third quarter valued at about $27,000. Ashton Thomas Private Wealth LLC purchased a new stake in shares of Globus Medical during the second quarter valued at approximately $33,000. Quarry LP raised its stake in shares of Globus Medical by 698.4% during the third quarter. Quarry LP now owns 495 shares of the medical device company’s stock valued at $35,000 after purchasing an additional 433 shares during the period. Farther Finance Advisors LLC lifted its position in shares of Globus Medical by 230.5% during the third quarter. Farther Finance Advisors LLC now owns 552 shares of the medical device company’s stock worth $39,000 after purchasing an additional 385 shares in the last quarter. Finally, International Assets Investment Management LLC purchased a new position in shares of Globus Medical in the second quarter valued at $52,000. 95.16% of the stock is owned by institutional investors and hedge funds.

About Globus Medical

Globus Medical, Inc, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives.